Abbott announced it has secured CE Mark for the world’s first dual glucose‑ketone sensing technology for people with diabetes. Branded as Libre Duo and Libre Duo 10 Day,… read more.
An AI-assisted model based on 71 different blood proteins could help doctors better predict retinal degeneration in diabetic patients before symptoms occur, according to a study published June… read more.
Researchers report that early treatment of type 2 diabetes with tirzepatide leads to greater improvements over 2 years in blood sugar, body weight, and waist size than treatment… read more.
The FDA has approved the supplemental biologic license application for Tzield (teplizumab-mzwv), expanding the indication from eight years and older to as young as one year of age… read more.
A new meta-analysis of relevant clinical studies suggests that GLP 1 weight-loss drugs provide protection against heart attacks, strokes and premature death for up to 2.7 years. The… read more.
A healthy diet, weight loss, and increased physical activity can effectively prevent type 2 diabetes. However, not all individuals at elevated diabetes risk benefit equally from lifestyle interventions…. read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for Kyinsu (insulin icodec + semaglutide, IcoSema) intended… read more.
A new analysis led by researchers at the Johns Hopkins Bloomberg School of Public Health finds that out-of-pockets caps on insulin for Medicare Part D beneficiaries have reined… read more.
Abbott announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology had better glucose outcomes than those using… read more.
A one-size-fits-all approach to prediabetes treatment may miss the opportunity to implement an early, more intensive, tailored prevention approach for those with the highest risk of developing Type… read more.
Eli Lilly and Company announced that access to self-pay pricing on the new Zepbound (tirzepatide) KwikPen for single-patient use will be available at LillyDirect and major pharmacies nationwide,… read more.
Researchers report that people with type 1 diabetes are nearly three times as likely to develop dementia compared to those without type 1 diabetes. The findings appeared in… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
